Biophytis SA (FR:ALBPS) has released an update.
Biophytis SA has filed an IND application with the FDA for a phase 2 clinical study in obesity using their drug candidate BIO101, targeting a market with potential revenues of $100 billion by 2030. The study, set to commence in mid-2024, aims to evaluate the efficacy and safety of BIO101 on muscle strength and body composition in obese patients. With an international multicenter approach, initial results are expected in 2025.
For further insights into FR:ALBPS stock, check out TipRanks’ Stock Analysis page.
